Abstract:Abstract With clinical success and FDA approval of Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, developing biotherapeutics against immune checkpoint targets, like CTLA-4, PD-1/PDL-1 and others, becomes hot pursuits for big pharma and biotech. However, traditional syngeneic models with surrogate murine reagents or human immune cell re-constitution in immune deficient mice are useful but not reliable and robust due to the species specificity and highly variable responses. It is crucial to establish additional preclinical models for efficacy assessment of investigational immune-oncology antibodies before entering clinic. Establishing human therapeutic target engineered mouse models by replacing mouse gene with human counterpart while maintaining intact mouse immunity is a practical approach for in vivo studies. Applying CRISPR-Cas9 and other gene editing techniques, we have engineered genetically a series of single and double human immune-checkpoint genes, like PD-1/PDL-1, CTLA-4, TIM3, CD137 and others, knock-in model expressing chimeric human/mouse targets composed of human extracellular domains, with intact mouse signal peptide and intracellular domain. FACS analysis of immune cells derived from homozygous knock-in mice showed that activated cells only express chimeric targets reactive to anti human target antibodies, but not mouse gene specific antibodies. We have been testing the efficacy of reference antibodies by treating these homozygous knock-in mice inoculated with syngeneic murine tumor cells. Other applications, like target validation, combination therapy and biomarker discovery, are also explored. Note: This abstract was not presented at the meeting. Citation Format: Gang Chen, Bin Cai, Feng Zhou, Jerry Zhou, Jie Liu, Xin Dong. Humanized mouse models for immune-oncology biotherapeutics: Development, validation and applications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1661. doi:10.1158/1538-7445.AM2017-1661

Bioengineering translational models of lymphoid tissues

Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs

Modeling immunity in microphysiological systems

Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays

Revolutionizing immune research with organoid-based co-culture and chip systems

Modeling Structural Elements and Functional Responses to Lymphatic-Delivered Cues in a Murine Lymph Node on a Chip

Engineering the Immune Microenvironment into Organoid Models

Engineering Biomaterials to Model Immune‐Tumour Interactions In Vitro

Tissue Engineering for Mimics and Modulations of Immune Functions

Microfluidic‐Based Reconstitution of Functional Lymphatic Microvasculature: Elucidating the Role of Lymphatics in Health and Disease

Synthetic cell-based tissues for bottom-up assembly of artificial lymphatic organs

Lymph Node-on-Chip Technology: Cutting-Edge Advances in Immune Microenvironment Simulation

Modeling human immune responses to vaccination in vitro

Applications of mechanistic modelling to clinical and experimental immunology: an emerging technology to accelerate immunotherapeutic discovery and development

Ex vivo Model of Functioning Human Lymph Node Reveals Pivotal Role for Innate Lymphoid Cells and Stromal Populations in Response to Vaccine Adjuvant

Biofabrication Directions in Recapitulating the Immune System-on-a-Chip

Modelling the tumor immune microenvironment for precision immunotherapy

Mouse models with human immunity and their application in biomedical research.

Abstract 1661: Humanized Mouse Models for Immune-Oncology Biotherapeutics: Development, Validation and Applications

Humanized Mouse Model for Evaluating Biocompatibility and Human Immune Cell Interactions to Biomaterials

Therapeutic synthetic and natural materials for immunoengineering